Literature DB >> 31010905

Health Supervision for Children With Neurofibromatosis Type 1.

David T Miller, Debra Freedenberg, Elizabeth Schorry, Nicole J Ullrich, David Viskochil, Bruce R Korf.   

Abstract

Neurofibromatosis type 1 (NF1) is a multisystem disorder that primarily involves the skin and peripheral nervous system. Its population prevalence is approximately 1 in 3000. The condition is usually recognized in early childhood, when pigmentary manifestations emerge. Although NF1 is associated with marked clinical variability, most children affected follow patterns of growth and development within the normal range. Some features of NF1 can be present at birth, but most manifestations emerge with age, necessitating periodic monitoring to address ongoing health and developmental needs and minimize the risk of serious medical complications. In this report, we provide a review of the clinical criteria needed to establish a diagnosis, the inheritance pattern of NF1, its major clinical and developmental manifestations, and guidelines for monitoring and providing intervention to maximize the health and quality of life of a child affected.
Copyright © 2019 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2019        PMID: 31010905     DOI: 10.1542/peds.2019-0660

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  26 in total

1.  Neurofibromatosis Type 1 Implicates Ras Pathways in the Genetic Architecture of Neurodevelopmental Disorders.

Authors:  Jessica A Kaczorowski; Taylor F Smith; Amanda M Shrewsbury; Leah R Thomas; Valerie S Knopik; Maria T Acosta
Journal:  Behav Genet       Date:  2020-02-05       Impact factor: 2.805

2.  Neurofibromatosis Type 1 With Cherubism-like Phenotype, Multiple Osteolytic Bone Lesions of Lower Extremities, and Alagille-syndrome: Case Report With Literature Survey.

Authors:  Reinhard E Friedrich; Jozef Zustin; Andreas M Luebke; Thorsten Rosenbaum; Martin Gosau; Christian Hagel; Felix K Kohlrusch; Ilse Wieland; Martin Zenker
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

3.  Parent-Reported Social Skills in Children with Neurofibromatosis Type 1: Longitudinal Patterns and Relations with Attention and Cognitive Functioning.

Authors:  Danielle M Glad; Christina L Casnar; Brianna D Yund; Kristin Lee; Bonita P Klein-Tasman
Journal:  J Dev Behav Pediatr       Date:  2021 Oct-Nov 01       Impact factor: 2.225

Review 4.  [Neurofibromatosis type 1 : From diagnosis to follow-up].

Authors:  Rebecca Anders; Franz Wolfgang Hirsch; Christian Roth
Journal:  Radiologie (Heidelb)       Date:  2022-09-07

5.  Tumor and Constitutional Sequencing for Neurofibromatosis Type 1.

Authors:  Schuyler Tong; W Patrick Devine; Joseph T Shieh
Journal:  JCO Precis Oncol       Date:  2022-05

6.  Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients.

Authors:  Sara Lomelino Pinheiro; Joana Maciel; Daniela Cavaco; Ana Abrantes Figueiredo; Inês Lemos Damásio; Sara Donato; João Passos; Joana Simões-Pereira
Journal:  Hormones (Athens)       Date:  2022-10-21       Impact factor: 3.419

Review 7.  Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations.

Authors:  Benjamin Chevalier; Hippolyte Dupuis; Arnaud Jannin; Madleen Lemaitre; Christine Do Cao; Catherine Cardot-Bauters; Stéphanie Espiard; Marie Christine Vantyghem
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-06       Impact factor: 5.555

Review 8.  Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.

Authors:  Robert Galvin; Adrienne L Watson; David A Largaespada; Nancy Ratner; Sara Osum; Christopher L Moertel
Journal:  Curr Oncol Rep       Date:  2021-03-15       Impact factor: 5.075

9.  Legius Syndrome and its Relationship with Neurofibromatosis Type 1.

Authors:  Ellen Denayer; Eric Legius
Journal:  Acta Derm Venereol       Date:  2020-03-25       Impact factor: 3.875

Review 10.  Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA.

Authors:  Claudia Piombino; Laura Cortesi; Matteo Lambertini; Kevin Punie; Giovanni Grandi; Angela Toss
Journal:  J Oncol       Date:  2020-07-14       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.